Formulation Development
Terumo Announces Completion of Acquisition of WuXi Biologics Drug Product Plant in Leverkusen, Germany
Terumo Corporation recently announced the successful completion of its acquisition of a Drug Product Plant and associated Quality Control Laboratory operations from WuXi Biologics in Leverkusen,…
WHITE PAPER - An Insoluble Problem? Overcoming Oral Drug Solubility Challenges With Functional Polymers
There are three key factors that need to be controlled when designing a drug product for solubility enhancement: the polymeric carrier; the manufacturing process; and the match to the desired API. By controlling these three factors bioavailability, drug release profile and manufacturability of your final drug product can be controlled.
NanoPhoria Bioscience Secures Funding to Advance Breakthrough Heart Failure Therapy & Expand Portfolio for Novel Nano-in-Micro Delivery Platform
NanoPhoria Bioscience recently announced the successful first close of its €83.5 million Series A financing round. The round was led by XGEN Venture, Sofinnova Partners,…
Oculis Accelerates Privosegtor Into Registrational Trials in Acute Optic Neuritis, Pioneering the Path for a Potential First-in-Class Neuroprotective Therapy
Oculis Holding AG recently announced the advancement of Privosegtor into a registrational program for neuro-ophthalmology indications following a positive meeting with the US FDA. Privosegtor…
Dyadic Applied BioSolutions Announces Milestone Achievements & Recent Company Developments
Dyadic International, Inc. recently announced the achievement of additional milestone payments in its collaborations with Proliant Health & Biologicals in life sciences and Inzymes ApS…
Invivyd Announces US IND Clearance & Alignment With FDA on Pivotal Clinical Program for a Vaccine-Alternative Antibody to Prevent COVID
Invivyd, Inc. recently announced the US FDA has cleared the company’s Investigational New Drug (IND) application and provided feedback to advance the company’s REVOLUTION clinical…
uniQure’s Gene Therapy for Huntington’s Disease Holds Blockbuster Potential
uniQure recently announced that its novel gene therapy, AMT-130 (ifezuntirgene inilparvovec), demonstrated statistically significant disease slowing in a Huntington’s disease (HD) pivotal trial. The results…
Polyrizon Announces Positive Pre-Clinical Results: PL-14 Demonstrates Encouraging Allergen-Blocking Efficacy
Polyrizon Ltd. recently announced encouraging results from a recent pre-clinical study evaluating the allergen-blocking performance of its PL-14 Allergy Blocker formulation. The study was designed…
Ovid Announces Positive Topline Results for the Next-Generation GABA-Aminotransferase Inhibitor
Ovid Therapeutics Inc. recently announced positive topline results from its Phase 1 healthy volunteer study evaluating the safety, tolerability, pharmacokinetic (PK) and pharmacodynamic (PD) activity…
AM-Pharma Completes Enrollment in Phase 2 Study of Ilofotase Alfa for Prevention of Cardiac Surgery-Associated Renal Damage
AM-Pharma B.V. recently announced that it has successfully completed enrollment of patients in its ongoing Phase 2 clinical trial evaluating ilofotase alfa for the prevention…
Bio-Rad Extends Partnership With Gencurix Through Strategic Agreement for Droplet Digital PCR IVD Oncology Kits in Europe
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, and Gencurix, Inc. (KOSDAQ: 229000), a leading…
Draig Therapeutics Announces US FDA Clearance of IND Application for Phase 2 Study for the Treatment of Major Depressive Disorder
Draig Therapeutics recently announces that it will initiate a Phase 2 study of DT-101, a next-generation AMPA receptor positive allosteric modulator (PAM) for Major Depressive…
Sitryx Receives FDA Clearance of IND Application for Atopic Dermatitis Treatment
Sitryx Therapeutics recently announced it has received clearance from the US FDA for its Investigational New Drug (IND) application for SYX-5219, to support the initiation…
Aerska Launches With $21 Million in Financing to Develop RNAi Medicines for Diseases of the Brain
Aerska, a biotechnology company aiming to redefine the treatment of neurological diseases, recently announced it has raised $21 million in seed financing, co-led by Age1,…
RheumaGen Announces Oral Presentation on HLA Gene-Editing Preclinical Data for Lead Autoimmune Disease Program at ACR Convergence 2025
RheumaGen, Inc., a cell and gene therapy company engineering a new class of therapeutics for major autoimmune diseases, today announced that a human leukocyte antigen…
Fortress Biotech & Urica Therapeutics Announce Crystalys Therapeutics’ $205 Million Series A Financing
Urica Therapeutics, Inc., a Fortress Biotech, Inc. subsidiary, recently announced Crystalys Therapeutics, Inc., in which Urica maintains an equity position, closed a $205 million Series…
VERAXA Biotech & Secarna Pharmaceuticals Initiate Antibody Oligonucleotide Conjugate Alliance in Immunology
VERAXA Biotech, an emerging leader in designing novel cancer therapies and proposed de-SPAC acquisition target of Voyager Acquisition Corp. and Secarna Pharmaceuticals GmbH & Co. KG,…
Sharp Appoints Samantha Wilson Jones as General Counsel
Sharp Services, a leader in pharmaceutical packaging, clinical trial services & sterile manufacturing, has appointed Samantha Wilson Jones as General Counsel and Corporate Secretary of…
Orexo US Awarded $8 Million by BARDA for OX390 Development Partnership
Orexo AB recently announced its wholly owned US subsidiary, Orexo US, Inc., has been awarded USD 8 million in funding by the Biomedical Advanced Research…
Navigating the Fill Finish Process - e-book
You’re here, likely because you are seeking formulation, sterilization, and filling services for your drug. Our guide maps out the journey from onboarding to batch release and highlights facility differences between CMOs so you can understand the impact on your product quality and safety. So, let’s get started!
